INTRODUCTION: Incidental pancreatic cystic lesions (IPCL) are becoming an increasingly frequent clinical entity. Within this review, the differential diagnosis, investigation, and management are discussed. METHODS: A MEDLINE search was performed for IPCL. RESULTS: Incidence of IPCL varies from 0.2-0.7%, and 30-47% are premalignant or malignant. Pancreatic pseudocysts (PC), serous cystic neoplasms (SCN), intraductal papillary mucinous neoplasms (IPMN), and mucinous cystic neoplasms (MCN) are the most common pathological entities of IPCL. The use of combined modalities, including clinical characteristics, serum tumor markers, cross-sectional imaging, and endoscopic ultrasound (EUS) with cyst fluid analysis should all be used to establish an accurate preoperative diagnosis if possible. Modern multidetector computed tomography (MDCT) and magnetic resonance pancreatography (MRP) allow detailed characterization of IPCL, including size, septation, calcifications, mural nodules, and communication with main pancreatic duct. The best available cyst fluid markers of mucinous neoplasm are viscosity > or =1.6 and carcinoembryonic antigen >192 ng/ml. Although surgery is indicated for MCN or main or mixed duct IPMN, recent advances in the understanding of the natural history and increasingly accurate preoperative diagnosis allow a nonoperative approach to be undertaken for the majority of IPCL. For those treated nonoperatively, the ideal follow-up has yet to be determined. CONCLUSIONS: Emerging evidence supports selective nonoperative management for the majority of patients who have IPCL when investigated by a multimodal approach. For those in whom a suspicion of malignancy remains, surgery is indicated.
INTRODUCTION: Incidental pancreatic cystic lesions (IPCL) are becoming an increasingly frequent clinical entity. Within this review, the differential diagnosis, investigation, and management are discussed. METHODS: A MEDLINE search was performed for IPCL. RESULTS: Incidence of IPCL varies from 0.2-0.7%, and 30-47% are premalignant or malignant. Pancreatic pseudocysts (PC), serous cystic neoplasms (SCN), intraductal papillary mucinous neoplasms (IPMN), and mucinous cystic neoplasms (MCN) are the most common pathological entities of IPCL. The use of combined modalities, including clinical characteristics, serum tumor markers, cross-sectional imaging, and endoscopic ultrasound (EUS) with cyst fluid analysis should all be used to establish an accurate preoperative diagnosis if possible. Modern multidetector computed tomography (MDCT) and magnetic resonance pancreatography (MRP) allow detailed characterization of IPCL, including size, septation, calcifications, mural nodules, and communication with main pancreatic duct. The best available cyst fluid markers of mucinous neoplasm are viscosity > or =1.6 and carcinoembryonic antigen >192 ng/ml. Although surgery is indicated for MCN or main or mixed duct IPMN, recent advances in the understanding of the natural history and increasingly accurate preoperative diagnosis allow a nonoperative approach to be undertaken for the majority of IPCL. For those treated nonoperatively, the ideal follow-up has yet to be determined. CONCLUSIONS: Emerging evidence supports selective nonoperative management for the majority of patients who have IPCL when investigated by a multimodal approach. For those in whom a suspicion of malignancy remains, surgery is indicated.
Authors: Carlos Fernández-del Castillo; Javier Targarona; Sarah P Thayer; David W Rattner; William R Brugge; Andrew L Warshaw Journal: Arch Surg Date: 2003-04
Authors: Jennifer F Tseng; Andrew L Warshaw; Dushyant V Sahani; Gregory Y Lauwers; David W Rattner; Carlos Fernandez-del Castillo Journal: Ann Surg Date: 2005-09 Impact factor: 12.969
Authors: Dushyant V Sahani; Rajgopal Kadavigere; Anuradha Saokar; Carlos Fernandez-del Castillo; William R Brugge; Peter F Hahn Journal: Radiographics Date: 2005 Nov-Dec Impact factor: 5.333
Authors: Sang Hyub Lee; Cheol Min Shin; Joo Kyung Park; Sang Myung Woo; Ji Won Yoo; Ji Kon Ryu; Yong Bum Yoon; Yong-Tae Kim Journal: Dig Dis Sci Date: 2007-04-03 Impact factor: 3.199
Authors: Debashish Bose; Eric Tamm; Jun Liu; Leonardo Marcal; Aparna Balachandran; Priya Bhosale; Jason B Fleming; Jeffrey E Lee; Douglas B Evans; Rosa F Hwang Journal: J Am Coll Surg Date: 2010-06-08 Impact factor: 6.113
Authors: Mario Testini; Angela Gurrado; Germana Lissidini; Pietro Venezia; Luigi Greco; Giuseppe Piccinni Journal: World J Gastroenterol Date: 2010-12-07 Impact factor: 5.742
Authors: Linda M Pak; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Vinod P Balachandran; William R Jarnagin; Peter J Allen Journal: J Gastrointest Surg Date: 2017-05-17 Impact factor: 3.452
Authors: Nils Habbe; Jan-Bart M Koorstra; Joshua T Mendell; G Johan Offerhaus; Ji Kon Ryu; Georg Feldmann; Michael E Mullendore; Michael G Goggins; Seung-Mo Hong; Anirban Maitra Journal: Cancer Biol Ther Date: 2009-02-03 Impact factor: 4.742
Authors: Manoj K Bhasin; Kenneth Ndebele; Octavian Bucur; Eric U Yee; Hasan H Otu; Jessica Plati; Andrea Bullock; Xuesong Gu; Eduardo Castan; Peng Zhang; Robert Najarian; Maria S Muraru; Rebecca Miksad; Roya Khosravi-Far; Towia A Libermann Journal: Oncotarget Date: 2016-04-26